FAQ Directory

Here are some of the most frequently asked questions about NCQA’s various programs. If you don’t see what you are looking for in one of the entries below, you can ask a question through My NCQA.

Filter Results

You are viewing a single FAQ from your previous search. Clear Search

expand all

1.06.2017 Proportion of Days Covered by Medications The December 1, 2016 release of the PDC measure specification includes a new exclusion table, Renin Angiotensin System (RAS) Antagonists Exclusions (Table PDC-E). Row 10 of the “Overview” tab in the Excel file named “03_MY_2016_NDC_List_for_PQA-developed_measures_2016-12-01” includes the PQA Measure Drug Category: Insulin (exclusions), but corresponds to P4P table “PDC-E”, should this actually correspond with P4P table “PDC-D”?
If the above was an error, can you clarify where the codes for the ARB/Neprilysin Inhibitor Combination Medication (Table PDC-E) can be found?

You are correct, cell D-10 in the "Overview" tab should say "PDC-D" as this refers to the Insulin Exclusions (Table PDC-D) and NOT the Renin Angiotensin System (RAS) Antagonists Exclusions (Table PDC-E). We will fix this for the next release of the file and work with the measure developer to add an additional row that includes the exclusion table (PDC-E).

The data for the Renin Angiotensin System (RAS) Antagonists Exclusions (Table PDC-E) can currently be found in the RASA tab, in rows 4661-4672. This drug is also flagged in column L: "Denominator_Exclusion_Flag".

ALL 2016